PER-040-14招募中未知
A RANDOMISED, DOUBLE-BLIND, DOUBLE DUMMY, CHRONIC DOSING (56 WEEK)PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE, PHASE III STUDY TOEVALUATE THE EFFICACY AND SAFETY OF 3 DOSES OF BENRALIZUMAB (MEDI-563) INPATIENTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARYDISEASE (COPD) WITH A HISTORY OF COPD EXACERBATIONS (TERRANOVA)
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40 至 85（—）
- 性别
- All
入选标准
- •1.Provision of informed consent prior to any study specific procedures.
- •2.Female or male subjects aged 40-85 years inclusive
- •3.History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC<0.70 and a post-bronchodilator FEV1>20% and ≤65% of predicted normal value at screening (central spirometry will be used for this criteria assessment).
- •4.History of 2 or more moderate COPD exacerbations that required treatment with systemic corticosteroids and/or antibiotics,
- •5.mMRC score ≥1 at Visit 1
- •6.Subjects should have evidence of having been treated with double (ICS/LABA or LABA/LAMA) or triple (ICS/LABA/LAMA) therapy approved for COPD in a given country in the year prior to enrolment (Visit 1).
- •Women of childbearing potential (WOCBP) must use a highly effective form of birth control (confirmed by the Investigator).
- •7.Male subjects who are sexually active must be surgically sterile at least one year prior to Visit 1 or must use an adequate method of contraception Ability to read, write and use electronic devices.
- •Additional criteria to be checked prior to randomisation:
- •8.Blood eosinophils.
- •9.Compliance with the eDiary
- •At least 70% compliance with the subject’s maintenance therapy
排除标准
- •1.Clinically important pulmonary disease other than COPD
- •2.Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator
- •3.Unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, renal failure, uncontrolled hypertension as defined by the Investigator
- •4.Treatment with systemic corticosteroids and/or antibiotics,
- •5.Acute upper or lower respiratory infection requiring antibiotics or antiviral medication within 2 weeks prior to enrolment (Visit 1).
- •6.Pneumonia within 8 weeks prior to enrolment (Visit 1), based on the last day of antibiotic treatment or hospitalization date, whatever occurred later.
- •7.Pregnant, breastfeeding, or lactating women.
- •8.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥1.5 times the upper limit of normal (ULN) confirmed by repeated testing during screening period
- •9.Risk factors for pneumonia (immunosuppression, neurological disorder with increased risk of aspiration).
- •10.Known history of allergy or reaction to any component of the investigational product formulation.
- •11.History of anaphylaxis to any other biologic therapy.
- •12.Donation of blood, plasma or platelets within the past 90 days prior to Visit 1.
- •13.Long term oxygen therapy (LTOT) with signs and/or symptoms of cor pulmonale and/or right ventricular failure..
- •14.Use of any non-invasive positive pressure ventilation device (NIPPV)..
研究者
相似试验
进行中（未招募）
不适用
ot applicableEUCTR2013-000116-14-ITALMIRALL, S. A., Research and Development (R&D) Centre900
进行中（未招募）
1 期
ot applicableEUCTR2013-000116-14-GBALMIRALL, S. A., Research and Development (R&D) Centre933
进行中（未招募）
不适用
A CLINICAL STUDY TO COMPARE TWO DRUGS: ACLIDINIUMBROMIDE/FORMOTEROL FUMARATE (treatment 1) COMPARED WITHSALMETEROL/FLUTICASONE PROPRIONATE (treatment 2) FOR 24-WEEKSTREATMENT IN SYMPTOMATIC PATIENTS WITH CHRONIC OBSTRUCTIVEPULMONARY DISEASE (COPD). THE STUDY IS RANDOMISED (EQUALCHANCE OF RECEIVING TREATMENT 1 or TREATMENT 2) AND DOUBLEBLIND (NEITHER PATIENTS NOR THE STUDY DOCTOR WILL KNOW THETREATMENT)EUCTR2013-000116-14-CZALMIRALL, S. A., Research and Development (R&D) Centre900
已完成
3 期
A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF TWICE-DAILY ACLIDINIUM BROMIDE /FORMOTEROL FUMARATE COMPARED WITH TWICE-DAILY SALMETEROL/FLUTICASONE PROPIONATE FOR 24-WEEKS TREATMENT IN SYMPTOMATIC PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)NL-OMON40490Almirall, S.A.20
进行中（未招募）
不适用
A CLINICAL STUDY TO COMPARE TWO DRUGS: ACLIDINIUM BROMIDE/ FORMOTEROL FUMARATE (treatment 1) COMPARED WITH SALMETEROL/ FLUTICASONE PROPRIONATE (treatment 2) FOR 24-WEEKS TREATMENT IN SYMPTOMATIC PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). THE STUDY IS RANDIMISED (EQUAL CHANCE OF RECEIVING TREATMENT 1 OR TREATMENT 2) AND DOUBLE BLIND(NEITHER PATIENTS NOR THE STUDY DOCTOR WILL KNOW THE TREATMENT)Chronic obstructive pulmonary disease (COPD)MedDRA version: 16.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2013-000116-14-BGALMIRALL, S. A., Research and Development (R&D) Centre933